Understanding progression rates and why early treatment matters
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
"Just keep an eye on it" is reasonable advice for a single, stable actinic keratosis — but it's natural to wonder what you're actually risking by not treating one at all. Our companion article, What Is an Actinic Keratosis, and How Is It Different From Skin Cancer?, covers how AK differs from cancer and the clinical signs that suggest a spot is progressing. This article picks up from there and focuses on the real-world stakes: what progression actually costs you biologically and in treatment, which patients carry meaningfully higher risk, and why "doing nothing indefinitely" isn't the neutral option it can feel like.
If you're trying to decide whether a specific lesion needs treatment right now versus watchful waiting, see How Do I Know Whether an AK Needs Treatment Now or Can Be Watched Safely? for that decision framework. Here, the question is simpler: why does leaving AK untreated carry risk in the first place?
An AK's abnormal keratinocytes start out confined to the epidermis, with no access to blood vessels or lymphatic channels. Progression is a biological transition, not just a cosmetic change: as abnormal cells accumulate additional DNA damage from ongoing UV exposure, they can begin breaching the basement membrane that separates the epidermis from the dermis below.
Once that boundary is crossed, the lesion is reclassified as an invasive squamous cell carcinoma (SCC). It now has access to the blood supply and lymphatic system, which is what gives a cancer the capacity to grow more aggressively, invade nearby structures like nerves, cartilage, or muscle, and — in a minority of cases — spread to regional lymph nodes or distant sites. None of that capability exists while the abnormal cells stay above the basement membrane, which is exactly why "in situ" disease and invasive disease are treated so differently.
The often-quoted "less than 1% per year" progression estimate for a single AK is an average across a very mixed population. It understates the real risk for several identifiable groups:
This is the single biggest risk multiplier. Long-term immunosuppression to prevent organ rejection also disables much of the immune system's ability to police abnormal keratinocytes. Transplant recipients face an estimated 65- to 250-fold increase in cutaneous SCC compared with the general population, and their AKs tend to progress faster, behave more aggressively, and are more likely to metastasize once they do become invasive.
Someone with a single small AK and someone with dozens of AKs across chronically sun-damaged skin are not facing the same odds. Field cancerization means the visible AKs are only the tip of a much larger area of UV-damaged, genetically abnormal skin — more affected tissue means more chances for one lesion, somewhere in that field, to accumulate the mutations needed to invade.
An AK that keeps coming back in the same spot after treatment, or one that has never fully resolved, has had more cumulative opportunity to accumulate the genetic changes associated with invasion. Persistence itself is a risk signal, distinct from any single visual feature.
AKs on the ears, lips (actinic cheilitis), and scalp are associated with a higher likelihood of progression and, when they do progress, a higher likelihood of aggressive behavior — these areas have thinner skin, less underlying fat, and closer proximity to cartilage, nerves, and lymphatic drainage.
"Watching and doing nothing indefinitely" isn't a neutral, zero-cost choice — it's a bet that a given lesion won't be the one that crosses the line, and if that bet is lost, the treatment path changes dramatically. An untreated AK that progresses to SCC generally can't be managed with the quick, low-morbidity options used for AK itself.
It's true, and worth repeating: most individual AKs never progress to cancer. That fact and the case for treating them are not actually in tension, for two reasons.
First, risk compounds. A less-than-1%-per-year estimate for one lesion sounds negligible, but it's rarely just one lesion, and rarely just one year. Someone with sun damage significant enough to produce AKs typically has several, over years or decades — and a small per-lesion, per-year probability multiplied across many lesions and a long time horizon adds up to a real, non-trivial lifetime probability that something eventually progresses.
Second, the asymmetry in effort is enormous. Treating an AK today is quick, low-cost, and low-morbidity — cryotherapy takes moments, and topical field therapy is a matter of weeks of at-home cream. Treating an established SCC tomorrow means surgery, possible reconstruction, and a meaningfully longer recovery. Early treatment isn't just statistically favorable; it trades a small, certain inconvenience now for protection against a much larger, uncertain one later.
Most actinic keratoses never become cancer, and that's genuinely reassuring. But "usually fine" is not the same as "no cost to ignoring it forever" — especially for people carrying more risk than average: those who are immunosuppressed, those with extensive field cancerization, and those with chronic or high-risk-location lesions. For those groups in particular, the calculus shifts meaningfully toward treating rather than watching.
The larger point holds for everyone, though: treating an AK today is about as low-stakes as skin cancer prevention gets, and the alternative — an established SCC — is a meaningfully bigger problem to solve. That asymmetry, more than any single statistic, is the real argument for early treatment.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Only a dermatologist examining your skin in person — sometimes with a biopsy — can assess your individual risk and determine whether a specific lesion needs treatment.
Chat with our AI guide for personalized information about actinic keratosis and skin cancer
Chat with the Navigator